Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of February 2022, with a report date of February 8, 2022. The company is a British Virgin Islands corporation headquartered in Taizhou, Jiangsu, China.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on capital structure changes resulting from a recent public offering.
Material Changes
- Public Offering Completion: On January 20, 2022, the Company completed a firm commitment public offering consisting of 8,285,260 ordinary shares at $0.18 per share and 11,521,500 pre-funded warrants at $0.17 per warrant.
- Over-Allotment Exercise: The underwriter, Aegis Capital Corp., exercised an option to purchase an additional 2,971,014 ordinary shares.
- Warrant Exercise: As of February 8, 2022, investors exercised all pre-funded warrants to purchase 11,521,500 ordinary shares.
- Share Count Update: Following these transactions, the total number of issued and outstanding ordinary shares is 40,627,868.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items beyond the description of the capital raise.
Investor Verification Checklist
- Verify the total capital raised from the January 2022 offering and warrant exercises.
- Confirm the current share count of 40,627,868 against subsequent filings.
- Review the use of proceeds from the offering in the Company's Form 20-F or other financial statements.
- Check for any dilution impact on existing shareholders resulting from the pre-funded warrant exercises.